Guardant Health Ordered to Pay Over $245 Million in DNA Sequencing Patent Dispute
Court orders Guardant Health to pay over $245.2M for willfully infringing TwinStrand’s DNA sequencing patents. Ongoing 6% royalties apply; Guardant will appeal.
/ 7 items
#GH↓
Guardant Health Shares Surge as UnitedHealthcare Covers Shield Blood Test
UnitedHealthcare will begin reimbursing Guardant Health’s Shield colorectal cancer blood test from August 1, driving strong investor reaction and broader commercial access.
American Cancer Society Adds Easy Shield Blood Test to Colon Cancer Screening Guidelines
New blood test added to cancer screening guidelines makes it easier to check for colorectal cancer, helping more people get tested early.
FDA Approves Guardant360 Liquid CDx: The Largest Blood Test for Cancer Just Got 100x Smarter
FDA approved Guardant’s new blood test detects cancer DNA and signals from one sample for faster, smarter treatment decisions.
Guardant Health Shares Fall After FDA Raises Concerns on AstraZeneca Breast Cancer Drug
Guardant stock fell after FDA raised doubts on a key drug study. Delay fears hurt short-term, but long-term outlook still strong.
FDA Approves Guardant360 CDx for BRAF-Mutant Colorectal Cancer
Guardant Health’s Guardant360 CDx is now FDA-approved to identify BRAF V600E-mutant colorectal cancer patients, helping guide targeted therapy quickly with a simple blood test.